US Patent 10537638 Low concentration antibody formulations
Patent 10537638 was granted and assigned to GlaxoSmithKline on January, 2020 by the United States Patent and Trademark Office.
All edits
Edits on 11 Dec, 2023
Golden AI
Edits made to:
Article (+607 characters)
Article
Patent abstract
The present invention is directed formulations for low concentrations of therapeutic proteins and methods of making the same. In one aspect the present invention is directed to a formulation for a therapeutic protein comprising: a) the therapeutic protein; and b) a surfactant; wherein the molar ratio of surfactant to therapeutic protein is at least 100. In another aspect the present invention is directed to a formulation for a therapeutic protein comprising: a) the therapeutic protein; and b) an antioxidant, wherein the molar ratio of antioxidant to therapeutic protein is at least 750.
Edits on 4 Oct, 2023
Golden AI
Edits made to:
Infobox (+2 properties)
Infobox
Patent Inventor Names
George Crotts0
Sorina Morar-Mitrica0
Edits on 24 May, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 24 Apr, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
105376380
Date of Patent
January 21, 2020
0Patent Application Number
147759000
Date Filed
March 13, 2014
0Patent Primary Examiner
Edits on 1 Feb, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 10537638 Low concentration antibody formulations
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
10537638
Date of patent
January 21, 2020
Patent application number
14775900
Date Filed
March 13, 2014
Patent primary examiner
Find more entities like US Patent 10537638 Low concentration antibody formulations
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
